A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

Breast Cancer Research

Table 3 wGRS results of antimicrotubule agents, docetaxel, and paclitaxel-induced alopecia

Cat	Score	G2^a	G1^b	G0^c	%-G2	%-G1	%-G0	G2 vs. G0			G1 vs. G0
								OR^d*	95%CI	Pvalue	OR^d*	95%CI	Pvalue
Antimicrotubule (6 SNPs)
1	<5.56	2	7	34	0.05	0.16	0.79		Ref			Ref
2	5.56-7.60	25	20	50	0.26	0.21	0.53	8.50	1.89-38.3	1.66E-03	1.94	0.74-1.42	2.52E-01
3	7.60-9.63	65	17	19	0.64	0.17	0.19	58.2	12.8-265	4.93E-14	4.35	1.53-12.4	6.42E-03
4	>9.63	26	6	1	0.79	0.18	0.03	442	38.0-5140	2.71E-14	29.1	3.02-282	8.39E-04
	Total	118	50	104
Docetaxel (4 SNPs)
1	<2.26	1	5	23	0.03	0.17	0.79		Ref			Ref
2	2.26-4.70	9	6	14	0.31	0.21	0.48	14.8	1.69-130	4.39E-03	1.97	0.51-7.68	4.88E-01
3	4.70-7.15	33	5	4	0.79	0.12	0.10	190	19.9-1810	1.01E-11	5.75	1.12-29.4	4.08E-02
4	>7.15	19	2	0	0.90	0.10	0.00	611	23.5-15900	2.50E-11	21.4	0.89-511	4.83E-02
	Total	62	18	41
Paclitaxel (7 SNPs)
1	<3.24	2	4	28	0.06	0.12	0.82		Ref			Ref
2	3.24-7.48	4	14	22	0.10	0.35	0.55	2.55	0.43-15.2	4.01E-01	4.46	1.28-1.92	2.60E-02
3	7.48-11.7	35	12	11	0.60	0.21	0.19	44.6	9.12-218	9.55E-10	7.64	2.02-28.9	2.30E-03
4	>11.7	16	5	0	0.76	0.24	0.00	376	17.0-8320	1.54E-10	69.7	3.26-1490	2.89E-04
	Total	57	35	61

^aIndividuals who developed grade 2 alopecia; ^bindividuals who developed grade 1 alopecia; ^cindividuals who did not developed any ADRs after chemotherapy; ^dORs and CIs are calculated using category (group) 1 as reference. *OR calculated after Haldane’s correction: adding 0.5 to all the cells of a contingency table if any of the cell expectations would cause a division by zero error. Cat, category; OR, odds ratio; CI, confidence interval; Ref, reference.

ISSN: 1465-542X